Natera President of Clinical Diagnostics Sells $1.24M in Common Stock Under Rule 10b5-1 Plan

Executive Summary

On October 1, 2026, Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ: NTRA), executed open-market sales totaling 3,000 shares of common stock for an aggregate value of approximately $1,242,645.26. The sales were executed in three weighted-average price tranches ranging from $411.62 to $415.07 pursuant to a pre-established Rule 10b5-1 trading plan.

Transaction Details

• Tranche 1: 200 shares sold at a weighted average price of $411.62 (range: $411.55 – $411.69).
• Tranche 2: 954 shares sold at a weighted average price of $413.1066 (range: $412.8350 – $413.3100).
• Tranche 3: 1,846 shares sold at a weighted average price of $415.0691 (range: $414.44 – $415.19).
• Total Volume: 3,000 shares.
• Blended Average Price: ~$414.22 per share.

Context and Market Significance

• Rule 10b5-1 Plan: The transactions were effected under a Rule 10b5-1 trading plan adopted on November 26, 2024. This pre-scheduled mechanism indicates the sales were planned well in advance and do not reflect short-term discretionary sentiment.
• Holding Impact: Following the transactions, Moshkevich maintains direct ownership of 106,914 shares. The disposition represents approximately 2.73% of his prior holdings (109,914 shares).
• Significance Level: Low. The routine nature of the Rule 10b5-1 plan combined with the modest percentage reduction of the executive's total equity stake suggests limited informational impact on market performance.